688319 欧林生物
交易中 03-11 13:20:44
资讯
新帖
简况
3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-09 16:20
3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股
3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-04
3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股
新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等
智通财经 · 03-02
新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等
股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元
证券之星 · 03-02
股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元
每周股票复盘：欧林生物（688319）2025年净利增7.1%
证券之星 · 03-01
每周股票复盘：欧林生物（688319）2025年净利增7.1%
欧林生物（688319）披露2025年年度业绩快报，2月27日股价上涨0.04%
证券之星 · 02-27
欧林生物（688319）披露2025年年度业绩快报，2月27日股价上涨0.04%
欧林生物（688319）披露股东减持股份计划公告，1月27日股价上涨0.19%
证券之星 · 01-27
欧林生物（688319）披露股东减持股份计划公告，1月27日股价上涨0.19%
欧林生物(688319.SH)：泰昌集团拟减持不超1.4789%股份
智通财经 · 01-27
欧林生物(688319.SH)：泰昌集团拟减持不超1.4789%股份
欧林生物（688319）披露关于诉讼进展暨本公司提起反诉的公告，1月26日股价上涨0.65%
证券之星 · 01-26
欧林生物（688319）披露关于诉讼进展暨本公司提起反诉的公告，1月26日股价上涨0.65%
【机构调研记录】西部利得基金调研欧林生物、润丰股份
证券之星 · 01-21
【机构调研记录】西部利得基金调研欧林生物、润丰股份
【机构调研记录】国联基金调研巨星农牧、欧林生物等5只个股（附名单）
证券之星 · 01-21
【机构调研记录】国联基金调研巨星农牧、欧林生物等5只个股（附名单）
【私募调研记录】神农投资调研欧林生物
证券之星 · 01-21
【私募调研记录】神农投资调研欧林生物
1月19日欧林生物涨9.21%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 01-19
1月19日欧林生物涨9.21%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）H股上市申请获证监会接收
证券之星 · 01-18
每周股票复盘：欧林生物（688319）H股上市申请获证监会接收
1月16日欧林生物跌15.21%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 01-16
1月16日欧林生物跌15.21%，兴全社会价值三年持有混合基金重仓该股
【机构调研记录】兴业基金调研欧林生物、泰胜风能
证券之星 · 01-12
【机构调研记录】兴业基金调研欧林生物、泰胜风能
【机构调研记录】东方基金调研欧林生物
证券之星 · 01-12
【机构调研记录】东方基金调研欧林生物
欧林生物（688319）披露限制性股票回购注销实施公告，01月09日股价上涨6.82%
证券之星 · 01-09
欧林生物（688319）披露限制性股票回购注销实施公告，01月09日股价上涨6.82%
欧林生物陷14年前技术合同纠纷，1920万资金遭冻结背后风险几何？
新浪证券 · 01-09
欧林生物陷14年前技术合同纠纷，1920万资金遭冻结背后风险几何？
每周股票复盘：欧林生物（688319）涉诉金额1920万元
证券之星 · 01-02
每周股票复盘：欧林生物（688319）涉诉金额1920万元
暂无数据
公司概况
公司名称：
成都欧林生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-08
主营业务：
成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。
发行价格：
9.88
{"stockData":{"symbol":"688319","market":"SH","secType":"STK","nameCN":"欧林生物","latestPrice":30.74,"timestamp":1773206444000,"preClose":30.85,"halted":0,"volume":5664989,"delay":0,"changeRate":-0.0036,"floatShares":405000000,"shares":405999999,"eps":0.1583,"marketStatus":"交易中","change":-0.11,"latestTime":"03-11 13:20:44","open":30.85,"high":32.18,"low":30.4,"amount":178000000,"amplitude":0.0577,"askPrice":30.75,"askSize":21,"bidPrice":30.74,"bidSize":38,"shortable":0,"etf":0,"ttmEps":0.1583,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773212400000},"marketStatusCode":2,"adr":0,"adjPreClose":30.85,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773192600000,1773199800000],[1773205200000,1773212400000]],"highLimit":33.94,"lowLimit":27.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":405708900,"isCdr":false,"pbRate":13.04,"roa":"--","peRate":194.18825,"roe":"5.02%","epsLYR":0.0512,"committee":0.698529,"marketValue":12471000000,"turnoverRate":0.014,"status":1,"floatMarketCap":12462000000},"requestUrl":"/m/hq/s/688319/tweets","defaultTab":"tweets","newsList":[{"id":"2618646350","title":"3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646350?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:20","pubTimestamp":1773044435,"startTime":"0","endTime":"0","summary":"证券之星消息，3月9日欧林生物涨6.87%，收盘报30.5元，换手率3.06%，成交量12.4万手，成交额3.67亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900020746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2616396580","title":"3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616396580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616396580?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:21","pubTimestamp":1772612518,"startTime":"0","endTime":"0","summary":"证券之星消息，3月4日欧林生物涨5.68%，收盘报28.65元，换手率2.26%，成交量9.17万手，成交额2.59亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400027747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2616334810","title":"新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334810?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:22","pubTimestamp":1772454137,"startTime":"0","endTime":"0","summary":"证监会要求欧林生物补充说明其及下属公司实际业务是否涉及《外商投资准入特别管理措施》中人体干细胞、基因诊断与治疗技术开发和应用，并提供明确依据。据港交所2025年11月25日披露，欧林生物递表港交所主板，中信证券为独家保荐人。招股书显示，欧林生物是一家面向全球、创新驱动的生物制药公司，致力于创新疫苗的研究、开发、生产及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","BK0239","688319","VT"],"gpt_icon":0},{"id":"2616765758","title":"股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616765758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616765758?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:49","pubTimestamp":1772390948,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩快报欧林生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利0.222亿元，同比增长7.1%。公司公告汇总成都欧林生物科技股份有限公司2025年年度业绩快报成都欧林生物科技股份有限公司发布2025年年度业绩快报，营业总收入为704,160,325.32元，同比增长19.58%；营业利润为30,857,171.48元，同比增长44.80%；利润总额为31,893,209.89元，同比增长43.00%；归属于母公司所有者的净利润为22,231,741.55元，同比增长7.10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2616843070","title":"每周股票复盘：欧林生物（688319）2025年净利增7.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843070?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:33","pubTimestamp":1772303590,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，欧林生物报收于27.5元，较上周的27.13元上涨1.36%。本周，欧林生物2月26日盘中最高价报28.3元。欧林生物当前最新总市值111.57亿元，在生物制品板块市值排名27/51，在两市A股市值排名1913/5189。公司公告汇总：归属于母公司的扣除非经常性损益的净利润同比减少11.64%。业绩披露要点欧林生物预计发布2025年年报，归属净利润为0.222亿元，同比增长7.1%。总资产为2,019,999,266.73元，较期初增长11.78%；归属于母公司的所有者权益为903,677,046.78元，较期初减少2.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2614857153","title":"欧林生物（688319）披露2025年年度业绩快报，2月27日股价上涨0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857153","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857153?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:06","pubTimestamp":1772204780,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，欧林生物报收于27.5元，较前一交易日上涨0.04%，最新总市值为111.57亿元。该股当日开盘27.32元，最高27.83元，最低27.19元，成交额达9451.61万元，换手率为0.85%。近日，成都欧林生物科技股份有限公司发布2025年年度业绩快报，营业总收入为704,160,325.32元，同比增长19.58%；营业利润为30,857,171.48元，同比增长44.80%；利润总额为31,893,209.89元，同比增长43.00%；归属于母公司所有者的净利润为22,231,741.55元，同比增长7.10%。归属于母公司所有者的扣除非经常性损益的净利润为9,879,538.77元，同比减少11.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2606738734","title":"欧林生物（688319）披露股东减持股份计划公告，1月27日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606738734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606738734?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:44","pubTimestamp":1769525056,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，欧林生物报收于26.33元，较前一交易日上涨0.19%，最新总市值为106.82亿元。该股当日开盘26.39元，最高26.69元，最低25.41元，成交额达1.74亿元，换手率为1.65%。近日，成都欧林生物科技股份有限公司发布《股东减持股份计划公告》。公告显示，截至公告披露日，泰昌集团有限公司持有公司25,893,040股，占总股本的6.38%，股份来源为IPO前取得。本次减持计划不会导致公司控制权变更，且符合此前已披露的承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700042196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2606047784","title":"欧林生物(688319.SH)：泰昌集团拟减持不超1.4789%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2606047784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606047784?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:08","pubTimestamp":1769519284,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧林生物(688319.SH)发布公告，因自身资金需求，泰昌集团计划根据市场情况通过集中竞价或者大宗交易的方式减持其所持有的IPO前公司股份合计不超过600万股，拟减持股份数量占公司当前总股本的比例不超过1.4789%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2606246720","title":"欧林生物（688319）披露关于诉讼进展暨本公司提起反诉的公告，1月26日股价上涨0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246720?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:26","pubTimestamp":1769437619,"startTime":"0","endTime":"0","summary":"近日，成都欧林生物科技股份有限公司发布《关于诉讼进展暨本公司提起反诉的公告》。公告显示，公司作为本诉被告、反诉原告，就王建华提起的诉讼案向四川省成都市中级人民法院提交反诉并获立案。本诉涉案金额为1,920万元，系王建华主张公司支付产品提成及违约金。公司请求法院确认合同已于2013年3月1日解除或判决解除合同，要求王建华返还已付款80万元并支付违约金890万元，承担诉讼费及律师费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600035888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2605614008","title":"【机构调研记录】西部利得基金调研欧林生物、润丰股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2605614008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605614008?lang=zh_cn&edition=full","pubTime":"2026-01-21 08:06","pubTimestamp":1768954010,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月20日披露的机构调研信息，西部利得基金近期对2家上市公司进行了调研，相关名单如下：1）欧林生物 调研纪要：重组金葡菌疫苗Ⅲ期临床未揭盲，预计2024年一季度完成血清检测，上半年阶段性锁库并首次揭盲。目前全球尚无金葡菌疫苗上市，市场空间广阔。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100005084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301035","BK0239","BK0229","688319"],"gpt_icon":0},{"id":"2605140017","title":"【机构调研记录】国联基金调研巨星农牧、欧林生物等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605140017?lang=zh_cn&edition=full","pubTime":"2026-01-21 08:06","pubTimestamp":1768953970,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月20日披露的机构调研信息，国联基金近期对5家上市公司进行了调研，相关名单如下：1）巨星农牧 调研纪要：公司2025年累计销售生猪458.09万头，商品肥猪完全成本约为6.5元/斤，12月完全成本降至6.0元/斤以内，PSY达30以上，育肥料肉比约2.5。目前全球尚无金葡菌疫苗上市，市场空间广阔。2025年整体毛利率预计与2024年基本持平，具体数据待年报披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100005045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","603477","BK0240","BK0239"],"gpt_icon":0},{"id":"2605140041","title":"【私募调研记录】神农投资调研欧林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605140041?lang=zh_cn&edition=full","pubTime":"2026-01-21 08:05","pubTimestamp":1768953942,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月20日披露的机构调研信息，知名私募神农投资近期对1家上市公司进行了调研，相关名单如下：1）欧林生物 调研纪要：重组金葡菌疫苗Ⅲ期临床未揭盲，预计2024年一季度完成血清检测，上半年阶段性锁库并首次揭盲。全球耐药负担重，2019年直接致死127万，2050年或增医疗支出1万亿美元。目前全球尚无金葡菌疫苗上市，市场空间广阔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026012100005002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2604859601","title":"1月19日欧林生物涨9.21%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604859601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604859601?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:36","pubTimestamp":1768808190,"startTime":"0","endTime":"0","summary":"证券之星消息，1月19日欧林生物涨9.21%，收盘报27.03元，换手率3.84%，成交量15.55万手，成交额4.23亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级3家，增持评级2家；过去90天内机构目标均价为27.72。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900014441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2604928580","title":"每周股票复盘：欧林生物（688319）H股上市申请获证监会接收","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928580","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928580?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:16","pubTimestamp":1768670170,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，欧林生物报收于24.75元，较上周的31.02元下跌20.21%。本周关注点交易信息汇总：欧林生物因股价跌幅达15%登上龙虎榜。公司已向中国证券监督管理委员会报送本次发行上市的备案申请材料，并于近日获得中国证监会接收。本次发行上市尚需取得中国证监会、香港证券及期货事务监察委员会和香港联交所等相关监管机构的批准、核准或备案，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2603968911","title":"1月16日欧林生物跌15.21%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603968911","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603968911?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:35","pubTimestamp":1768548950,"startTime":"0","endTime":"0","summary":"证券之星消息，1月16日欧林生物跌15.21%，收盘报24.75元，换手率4.67%，成交量18.94万手，成交额5.15亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级3家，增持评级2家；过去90天内机构目标均价为27.72。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600019360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2602565414","title":"【机构调研记录】兴业基金调研欧林生物、泰胜风能","url":"https://stock-news.laohu8.com/highlight/detail?id=2602565414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602565414?lang=zh_cn&edition=full","pubTime":"2026-01-12 08:01","pubTimestamp":1768176073,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月9日披露的机构调研信息，兴业基金近期对2家上市公司进行了调研，相关名单如下：1）欧林生物 调研纪要：公司重组金葡菌疫苗期中分析由DSMB独立揭盲，不影响样本量；因上市申报需完整数据，故未整体揭盲。兴业基金成立于2013年，截至目前，资产管理规模4171.34亿元，排名27/212；资产管理规模2452.86亿元，排名24/212；管理公募基金数207只，排名35/212；旗下公募基金经理28人，排名46/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0136","BK0028","688319","BK0070","300129","BK0224"],"gpt_icon":0},{"id":"2602412565","title":"【机构调研记录】东方基金调研欧林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2602412565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602412565?lang=zh_cn&edition=full","pubTime":"2026-01-12 08:01","pubTimestamp":1768176068,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月9日披露的机构调研信息，东方基金近期对1家上市公司进行了调研，相关名单如下：1）欧林生物 调研纪要：公司重组金葡菌疫苗期中分析由DSMB独立揭盲，不影响样本量；因上市申报需完整数据，故未整体揭盲。旗下最近一年表现最佳的公募基金产品为东方人工智能主题混合A，最新单位净值为1.88，近一年增长92.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2602374399","title":"欧林生物（688319）披露限制性股票回购注销实施公告，01月09日股价上涨6.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602374399?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:18","pubTimestamp":1767968302,"startTime":"0","endTime":"0","summary":"近日，成都欧林生物科技股份有限公司发布《2023年限制性股票激励计划首次授予部分第一类限制性股票回购注销实施公告》。公告显示，因2023年限制性股票激励计划首次授予部分第二个解除限售期公司层面业绩未达标，公司决定回购注销8名激励对象持有的224,700股第一类限制性股票，回购价格为10.59元/股加上银行同期存款利息。本次回购注销已于2025年10月28日经董事会审议通过，并经2025年11月14日股东大会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900040818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2602329069","title":"欧林生物陷14年前技术合同纠纷，1920万资金遭冻结背后风险几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602329069","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602329069?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:39","pubTimestamp":1767951540,"startTime":"0","endTime":"0","summary":" 近日，成都欧林生物科技股份有限公司因两项核心疫苗产品卷入合同纠纷，公司部分银行账户被法院冻结，引发市场关注。原告王建华主张公司支付技术提成及违约金共计1920万元，而该金额已超过欧林生物2025年上半年净利润。 欧林生物此次诉讼虽源于14年前的合同，却反映出公司在上市前后信息披露的一致性、技术合作管理的规范性以及法律风险防控意识等方面仍有提升空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-01-09/doc-inhftcfm2875094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2600775036","title":"每周股票复盘：欧林生物（688319）涉诉金额1920万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600775036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600775036?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:32","pubTimestamp":1767295932,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，欧林生物报收于25.65元，较上周的25.34元上涨1.22%。本周，欧林生物12月22日盘中最高价报26.36元。公司公告汇总：欧林生物与科园信海签署补充协议，推广协议有效期延长至2029年12月31日。公司公告汇总成都欧林生物科技股份有限公司收到法院通知，王建华起诉公司要求支付技术提成1600万元及违约金320万元，合计1920万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773206451708,"stockEarnings":[{"period":"1week","weight":0.138},{"period":"1month","weight":0.3078},{"period":"3month","weight":0.1847},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.9738},{"period":"ytd","weight":0.2165}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":0.0142},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.064},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都欧林生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10200人(较上一季度增加56.42%)","perCapita":"39746股","listingDate":"2021-06-08","address":"四川省成都市郫都区高新区天欣路99号","registeredCapital":"40570万元","survey":" 成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。","listedPrice":9.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧林生物,688319,欧林生物股票,欧林生物股票老虎,欧林生物股票老虎国际,欧林生物行情,欧林生物股票行情,欧林生物股价,欧林生物股市,欧林生物股票价格,欧林生物股票交易,欧林生物股票购买,欧林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}